CXCR4 and atopic eczema: As a novel and potent CXCR4 antagonist, EPI-X4 JM#21 is positioned in the text as a first-in-class inhibitor with therapeutic efficacy in treating atopic dermatitis, highlighting its importance (Harms et al., 2021).